Anti-NKG2D single domain-based antibodies for the modulation of anti-tumor immune response.

Humans Immunity Killer Cells, Natural NK Cell Lectin-Like Receptor Subfamily K Neoplasms Single-Domain Antibodies Tumor Microenvironment
HER2 NK cells NKG2D/NKG2DL axis cell engagers single-domain antibody

Journal

Oncoimmunology
ISSN: 2162-402X
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526

Informations de publication

Date de publication:
29 12 2020
Historique:
entrez: 18 1 2021
pubmed: 19 1 2021
medline: 29 7 2021
Statut: epublish

Résumé

The natural killer group 2 member D (NKG2D) receptor is a C-type lectin-like activating receptor mainly expressed by cytotoxic immune cells including NK, CD8

Identifiants

DOI: 10.1080/2162402X.2020.1854529 PMID: 33457075 PMC: PMC7781768
pubmed: 33457075
doi: 10.1080/2162402X.2020.1854529
pii: 1854529
pmc: PMC7781768
doi:

Substances chimiques

NK Cell Lectin-Like Receptor Subfamily K 0
Single-Domain Antibodies 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1854529

Informations de copyright

© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.

Références

Expert Opin Ther Targets. 2019 Apr;23(4):281-294
pubmed: 30732494
Proc Natl Acad Sci U S A. 2011 Mar 8;108(10):4081-6
pubmed: 21321202
Nature. 2002 Oct 17;419(6908):734-8
pubmed: 12384702
Front Immunol. 2019 May 28;10:1179
pubmed: 31231370
Int J Mol Sci. 2018 Jan 07;19(1):
pubmed: 29316666
Drug Discov Today. 2016 Jul;21(7):1076-113
pubmed: 27080147
Front Immunol. 2018 Mar 08;9:441
pubmed: 29568297
PLoS One. 2014 Oct 07;9(10):e108942
pubmed: 25291178
Cancer Immunol Res. 2018 Jul;6(7):776-787
pubmed: 29769244
Expert Opin Biol Ther. 2020 Dec;20(12):1491-1501
pubmed: 32726145
Oncotarget. 2017 Jan 10;8(2):2171-2186
pubmed: 27974689
Immunol Lett. 2002 Apr 22;81(2):141-8
pubmed: 11852119
Oncoimmunology. 2016 Sep 9;5(10):e1226720
pubmed: 27853650
Cell. 2018 Dec 13;175(7):1731-1743.e13
pubmed: 30503213
Front Immunol. 2018 Apr 23;9:827
pubmed: 29740438
Science. 2018 Mar 30;359(6383):1537-1542
pubmed: 29599246
Trends Immunol. 2019 Feb;40(2):142-158
pubmed: 30639050
Blood. 2006 Jan 1;107(1):159-66
pubmed: 16150947
J Immunol. 2019 Aug 1;203(3):676-685
pubmed: 31201235
Cancer Immun. 2013 May 01;13:8
pubmed: 23833565
Immunity. 2002 Jul;17(1):19-29
pubmed: 12150888
Front Immunol. 2018 Sep 11;9:2040
pubmed: 30254634
J Mol Biol. 2008 Dec 31;384(5):1143-56
pubmed: 18809410
Immune Netw. 2012 Dec;12(6):240-6
pubmed: 23396805
PLoS One. 2017 Jan 6;12(1):e0169535
pubmed: 28060885
Nat Rev Clin Oncol. 2017 Dec;14(12):717-734
pubmed: 28741618
Cancer Cell. 2017 Mar 13;31(3):383-395
pubmed: 28262555
Curr Opin Immunol. 2005 Feb;17(1):29-35
pubmed: 15653307
Front Immunol. 2018 Apr 27;9:929
pubmed: 29755480
Cancer Immunol Immunother. 2010 Aug;59(8):1197-209
pubmed: 20309546
Mediators Inflamm. 2020 Jul 24;2020:6437057
pubmed: 32774149
Int J Mol Sci. 2017 Aug 02;18(8):
pubmed: 28767057
Semin Immunol. 2017 Jun;31:64-75
pubmed: 28882429
J Leukoc Biol. 2020 Sep 29;:
pubmed: 32991746
Mol Cell Proteomics. 2014 Feb;13(2):653-65
pubmed: 24361863
MAbs. 2009 Mar-Apr;1(2):115-27
pubmed: 20061825
Cancer Res. 2002 Nov 1;62(21):6178-86
pubmed: 12414645
Front Immunol. 2018 Feb 12;9:231
pubmed: 29483917
Vet Microbiol. 2007 Mar 10;120(3-4):193-206
pubmed: 17127019
Mol Biosyst. 2012 Sep;8(9):2385-94
pubmed: 22772166
Neoplasia. 2017 Jun;19(6):471-482
pubmed: 28499126
Antibodies (Basel). 2015 Dec 26;5(1):
pubmed: 31557983
Mol Cancer Ther. 2013 Aug;12(8):1481-91
pubmed: 23757164
Blood. 2010 Mar 18;115(11):2167-76
pubmed: 19965656
Blood. 2014 Jan 30;123(5):678-86
pubmed: 24326534
Nat Rev Drug Discov. 2015 Aug;14(8):561-84
pubmed: 26228759
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
Cell. 2019 Jun 13;177(7):1701-1713.e16
pubmed: 31155232
Mol Immunol. 2005 Feb;42(4):489-94
pubmed: 15607804
Oncotarget. 2014 Jul 30;5(14):5304-19
pubmed: 24979648
Front Immunol. 2017 Nov 22;8:1603
pubmed: 29213270
Front Immunol. 2018 Mar 12;9:476
pubmed: 29662484
Front Immunol. 2017 Nov 20;8:1589
pubmed: 29209322
Nat Immunol. 2008 May;9(5):503-10
pubmed: 18425107
Curr Opin Pharmacol. 2014 Aug;17:17-21
pubmed: 25011112
Leukemia. 2012 Apr;26(4):830-4
pubmed: 22005785
Cancer Immunol Res. 2015 Jun;3(6):575-82
pubmed: 26041808
Scand J Immunol. 2013 Aug;78(2):120-9
pubmed: 23679194
Cancer Immun. 2013;13:5
pubmed: 23390376
Immunol Rev. 2015 Sep;267(1):88-116
pubmed: 26284473
FEBS Lett. 1997 Sep 15;414(3):521-6
pubmed: 9323027
Immunity. 2003 Dec;19(6):803-12
pubmed: 14670298
Int J Cancer. 2014 Jun 15;134(12):2829-40
pubmed: 24242212

Auteurs

Adeline Raynaud (A)

Cancer Research Center of Marseille, INSERM, CNRS, Aix Marseille Université, Institut Paoli - Calmettes, Marseille, France.
Sanofi Oncology, Vitry-sur-Seine, France.

Klervi Desrumeaux (K)

Sanofi Oncology, Vitry-sur-Seine, France.

Laurent Vidard (L)

Sanofi Oncology, Vitry-sur-Seine, France.

Elise Termine (E)

Cancer Research Center of Marseille, INSERM, CNRS, Aix Marseille Université, Institut Paoli - Calmettes, Marseille, France.

Daniel Baty (D)

Cancer Research Center of Marseille, INSERM, CNRS, Aix Marseille Université, Institut Paoli - Calmettes, Marseille, France.

Patrick Chames (P)

Cancer Research Center of Marseille, INSERM, CNRS, Aix Marseille Université, Institut Paoli - Calmettes, Marseille, France.

Emmanuelle Vigne (E)

Sanofi Oncology, Vitry-sur-Seine, France.

Brigitte Kerfelec (B)

Cancer Research Center of Marseille, INSERM, CNRS, Aix Marseille Université, Institut Paoli - Calmettes, Marseille, France.
ORCID: 0000-0001-8423-3423

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Anti-NKG2D single domain-based antibodies for...
questionsmedicales.fr › Phénomènes du système immunitaire › Immunité › Anti-NKG2D single domain-based antibodies for...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Cellules tueuses naturelles › Anti-NKG2D single domain-based antibodies for...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs immunologiques › Récepteurs de cellules tueuses naturelles › Récepteurs de cellules NK de type lectine › Sous-famille K des récepteurs de cellules NK de type lectine › Anti-NKG2D single domain-based antibodies for...
questionsmedicales.fr › Tumeurs › Anti-NKG2D single domain-based antibodies for...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Fragments d'immunoglobuline › Fragments Fab d'immunoglobuline › Anticorps à domaine unique › Anti-NKG2D single domain-based antibodies for...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Microenvironnement cellulaire › Microenvironnement tumoral › Anti-NKG2D single domain-based antibodies for...